Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peripheral Vascular Disease Grows at Double-Digit Rates, Waits for Solutions

This article was originally published in Start Up

Executive Summary

New technologies are wanted for peripheral artery disease, which affects 12 to 14 million people in the US, two to three million of them serious enough to warrant intervention, according to "US Markets for Interventional Peripheral Vascular Disease Management Products and Technologies," a report recently issued by Windhover-Elsevier. In addition to peripheral arterial disease, approximately eight million people in the US suffer from chronic venous insufficiency, of whom more than three million develop venous ulcers. Aortic aneurysms affect another two million people in the US, and the prevalence is increasing due to the increasing number of the elderly. But one of the largest serious problems in peripheral vascular disease that has few solutions is deep vein thrombosis (DVT). In the US approximately 25 million suffer from this condition and two million more are diagnosed each year. DVT brings the danger of pulmonary embolism and death. These and other categories in peripheral vascular disease are forecast to grow by double-digit rates, including mechanical atherectomy systems, chronic total occlusion crossing systems, and endovascular cryotherapy systems.
Advertisement

Related Content

Embolic Protection: Unmet Clinical Need or Unneeded Technology
Invatec: Translating Global Success in Vascular Devices to the US Market
Covidien Set to Compete in Vascular Business
What's Next for Cardiovascular Systems?
Drug-Eluting Balloons: New Route to Revascularization
B. Braun's Bet on Balloons
Pathway Medical: Pursuing the Hawk
Peripheral Disease Moves to Center Stage
Vascular Architects: Going Against the Peripheral Flow
FoxHollow: Reviving Atherectomy

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel